Drug treatment with Cymbalta

ApprovedUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Depression

Conditions

Depression, Bereavement

Trial Timeline

Apr 1, 2008 → Apr 1, 2010

About Drug treatment with Cymbalta

Drug treatment with Cymbalta is a approved stage product being developed by Eli Lilly for Depression. The current trial status is unknown. This product is registered under clinical trial identifier NCT00658931. Target conditions include Depression, Bereavement.

What happened to similar drugs?

20 of 20 similar drugs in Depression were approved

Approved (20) Terminated (2) Active (0)
DuloxetineEli LillyApproved
duloxetineEli LillyApproved
DuloxetineEli LillyApproved
DuloxetineEli LillyApproved
DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00658931ApprovedUNKNOWN

Competing Products

20 competing products in Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
40
DuloxetineEli LillyApproved
35
FK949EAstellas PharmaPhase 3
40
QuetiapineAstellas PharmaPre-clinical
26
duloxetine + escitalopram + placeboEli LillyPhase 3
40
duloxetineEli LillyApproved
43
Duloxetine HydrochlorideEli LillyPhase 3
40
DuloxetineEli LillyApproved
43
DuloxetineEli LillyApproved
43
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
43
Duloxetine + PlaceboEli LillyPhase 3
40
DuloxetineEli LillyApproved
43
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
43
Olanzapine + PlaceboEli LillyPhase 3
40
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
32
duloxetine + duloxetineEli LillyPre-clinical
26
olanzapine + ziprasidoneEli LillyApproved
43
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
43
DuloxetineEli LillyApproved
43
DuloxetineEli LillyApproved
39